BRPI1014125A2 - composto, composição farmacêutica, e, uso de um composto. - Google Patents
composto, composição farmacêutica, e, uso de um composto.Info
- Publication number
- BRPI1014125A2 BRPI1014125A2 BRPI1014125A BRPI1014125A BRPI1014125A2 BR PI1014125 A2 BRPI1014125 A2 BR PI1014125A2 BR PI1014125 A BRPI1014125 A BR PI1014125A BR PI1014125 A BRPI1014125 A BR PI1014125A BR PI1014125 A2 BRPI1014125 A2 BR PI1014125A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009065029 | 2009-03-17 | ||
| PCT/JP2010/054291 WO2010106988A1 (ja) | 2009-03-17 | 2010-03-15 | アミド誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014125A2 true BRPI1014125A2 (pt) | 2016-04-12 |
Family
ID=42739647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014125A BRPI1014125A2 (pt) | 2009-03-17 | 2010-03-15 | composto, composição farmacêutica, e, uso de um composto. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8476253B2 (pt) |
| EP (1) | EP2409977A4 (pt) |
| JP (1) | JPWO2010106988A1 (pt) |
| KR (1) | KR20110136813A (pt) |
| CN (1) | CN102439007A (pt) |
| AU (1) | AU2010225747A1 (pt) |
| BR (1) | BRPI1014125A2 (pt) |
| CA (1) | CA2755697A1 (pt) |
| CO (1) | CO6450684A2 (pt) |
| IL (1) | IL215153A0 (pt) |
| MX (1) | MX2011009700A (pt) |
| NZ (1) | NZ595723A (pt) |
| RU (1) | RU2011141794A (pt) |
| SG (1) | SG174389A1 (pt) |
| TW (1) | TW201036964A (pt) |
| WO (1) | WO2010106988A1 (pt) |
| ZA (1) | ZA201106792B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011138916A1 (ja) * | 2010-05-07 | 2011-11-10 | 第一三共株式会社 | 多環式化合物 |
| US9745291B2 (en) * | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| WO2016022605A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CN110227164B (zh) | 2018-03-06 | 2021-11-23 | 江苏吉贝尔药业股份有限公司 | 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用 |
| CN119119063A (zh) | 2021-05-12 | 2024-12-13 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
| CN115466254A (zh) * | 2022-08-10 | 2022-12-13 | 安庆研至医药科技有限公司 | 一种抑制剂及其制备方法 |
| KR20250103719A (ko) | 2022-11-09 | 2025-07-07 | 베링거 인겔하임 인터내셔날 게엠베하 | cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체 |
| AU2023376006A1 (en) | 2022-11-09 | 2025-03-13 | Boehringer Ingelheim International Gmbh | Cyclic pyridine derivatives as cgas inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670048C3 (de) | 1966-01-26 | 1980-09-04 | C.H. Boehringer Sohn, 6507 Ingelheim | Neue Norscopolaminderivate |
| GB8929070D0 (en) | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
| DE4111243A1 (de) | 1991-04-08 | 1992-10-15 | Erbsloeh Julius & August | In laengsrichtung allseitig geschlossene, unloesbare, feste profilverbindung |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5576317A (en) | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
| CN1154240A (zh) * | 1995-11-06 | 1997-07-16 | 美国辉瑞有限公司 | 治疗癌症用的nk-1受体拮抗剂 |
| HUP9901639A3 (en) | 1996-01-26 | 2000-10-30 | Nattermann A & Cie | Therapeutic anti-asthma agents |
| PT1057827E (pt) | 1998-01-23 | 2003-11-28 | Sankyo Co | Derivados da espiropiperidina |
| HUP0104634A3 (en) * | 1998-07-06 | 2002-11-28 | Bristol Myers Squibb Co | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| US6809108B1 (en) | 1999-07-23 | 2004-10-26 | Banyu Pharmaceutical Co., Ltd. | Amide derivatives |
| TR200402367T4 (tr) | 2000-10-12 | 2004-12-21 | Boehringer Ingelheim Pharma Gmbh& Co.Kg | Yeni tiotropyum içeren inhalasyon tozları |
| CA2444395C (en) | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| US20040192728A1 (en) | 2003-02-03 | 2004-09-30 | Ellen Codd | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| AU2004231087B2 (en) | 2003-04-15 | 2007-01-04 | Merck Sharp & Dohme Corp. | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
| JP4853992B2 (ja) * | 2004-02-25 | 2012-01-11 | 第一三共株式会社 | インダノール誘導体 |
| AU2005214274A1 (en) * | 2004-02-25 | 2005-09-01 | Sankyo Company, Limited | Indanol derivative |
| JP2007528418A (ja) | 2004-03-11 | 2007-10-11 | セラヴァンス， インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物 |
| EP1723112A1 (en) | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2006160639A (ja) | 2004-12-06 | 2006-06-22 | Sankyo Co Ltd | ニューロキニン受容体拮抗剤と抗コリン剤の併用 |
| TW200714587A (en) * | 2005-03-10 | 2007-04-16 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2006099032A1 (en) * | 2005-03-10 | 2006-09-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2008546695A (ja) * | 2005-06-13 | 2008-12-25 | セラヴァンス， インコーポレーテッド | ムスカリン受容体アンタゴニストとして有用なビフェニル化合物 |
| JP2007084530A (ja) * | 2005-08-22 | 2007-04-05 | Sankyo Co Ltd | インダノール誘導体を含有する医薬組成物 |
| CN101678022A (zh) | 2006-12-21 | 2010-03-24 | 弗特克斯药品有限公司 | 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物 |
| WO2010007561A1 (en) * | 2008-07-15 | 2010-01-21 | Pfizer Limited | Novel compounds active as muscarinic receptor antagonists |
-
2010
- 2010-03-15 BR BRPI1014125A patent/BRPI1014125A2/pt not_active IP Right Cessation
- 2010-03-15 KR KR1020117021633A patent/KR20110136813A/ko not_active Withdrawn
- 2010-03-15 CA CA2755697A patent/CA2755697A1/en not_active Abandoned
- 2010-03-15 JP JP2011504832A patent/JPWO2010106988A1/ja not_active Withdrawn
- 2010-03-15 AU AU2010225747A patent/AU2010225747A1/en not_active Abandoned
- 2010-03-15 RU RU2011141794/04A patent/RU2011141794A/ru not_active Application Discontinuation
- 2010-03-15 NZ NZ595723A patent/NZ595723A/xx not_active IP Right Cessation
- 2010-03-15 EP EP10753480A patent/EP2409977A4/en not_active Withdrawn
- 2010-03-15 SG SG2011066347A patent/SG174389A1/en unknown
- 2010-03-15 CN CN2010800208688A patent/CN102439007A/zh active Pending
- 2010-03-15 WO PCT/JP2010/054291 patent/WO2010106988A1/ja not_active Ceased
- 2010-03-15 MX MX2011009700A patent/MX2011009700A/es active IP Right Grant
- 2010-03-16 TW TW099107542A patent/TW201036964A/zh unknown
-
2011
- 2011-09-15 IL IL215153A patent/IL215153A0/en unknown
- 2011-09-16 US US13/234,514 patent/US8476253B2/en not_active Expired - Fee Related
- 2011-09-16 ZA ZA2011/06792A patent/ZA201106792B/en unknown
- 2011-10-14 CO CO11136986A patent/CO6450684A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO6450684A2 (es) | 2012-05-31 |
| CA2755697A1 (en) | 2010-09-23 |
| RU2011141794A (ru) | 2013-04-27 |
| US20120071467A1 (en) | 2012-03-22 |
| TW201036964A (en) | 2010-10-16 |
| JPWO2010106988A1 (ja) | 2012-09-20 |
| NZ595723A (en) | 2012-10-26 |
| EP2409977A1 (en) | 2012-01-25 |
| ZA201106792B (en) | 2012-06-27 |
| SG174389A1 (en) | 2011-10-28 |
| CN102439007A (zh) | 2012-05-02 |
| EP2409977A4 (en) | 2012-09-26 |
| IL215153A0 (en) | 2011-12-29 |
| WO2010106988A1 (ja) | 2010-09-23 |
| US8476253B2 (en) | 2013-07-02 |
| AU2010225747A1 (en) | 2011-11-10 |
| KR20110136813A (ko) | 2011-12-21 |
| MX2011009700A (es) | 2011-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
| BRPI1009757A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1008498A2 (pt) | Composto, prodroga do composto, medicamento, e, uso de um composto. | |
| BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
| BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
| BRPI1012892A2 (pt) | composto, e, composição farmacêutica. | |
| BRPI0810161A2 (pt) | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto | |
| BRPI0915134A2 (pt) | composto, e, uso de um composto | |
| BRPI0906937A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BRPI1007186A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0915473A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0812942A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| BRPI0810019A2 (pt) | Composto, composição farmacêutica, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |